Skip to main content
. 2021 Aug 23;11:723753. doi: 10.3389/fonc.2021.723753

Figure 4.

Figure 4

Expression of tRF-31-U5YKFN8DYDZDD in GC serum.(A) The expression of tRF-31-U5YKFN8DYDZDD expression levels between GC (n = 111), gastritis patients (n = 48), and healthy volunteers (n = 89). (B) The expression levels of tRF-31-U5YKFN8DYDZDD in different pathologic stages of GC patients (stage I–II, n = 53; stage III–IV, n = 58). (C) Paired comparison of tRF-31-U5YKFN8DYDZDD in 28 pairs of preoperative and postoperative patients’ serums was determined using qRT-PCR. (D) Kaplan–Meier survival curves for 111 GC patients according to tRF-31-U5YKFN8DYDZDD expression status (log-rank test, P < 0.001).